Related Experiment Video

Updated: May 19, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Identification of new candidate therapeutic target genes in triple-negative breast cancer

Mathilde Glénisson1, Sophie Vacher, Céline Callens

  • 1Laboratory of Oncogenetic, Institut Curie, Hôpital René Huguenin, St-Cloud, France.

Genes & Cancer
|August 16, 2012
PubMed

Insights

Researchers identified new therapeutic targets for triple-negative breast cancer (TNBC). Six genes, including VEGFA and PARP1, were upregulated, suggesting potential biomarkers and drug targets for TNBC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) lacks targeted therapies due to negative estrogen/progesterone receptor and ERBB2 expression.
  • TNBC is known for aggressive behavior, necessitating the identification of novel therapeutic strategies.
  • Current treatment options for TNBC are limited, highlighting the need for new drug targets.

Purpose of the Study:

  • To identify novel therapeutic targets by analyzing mRNA expression in TNBC samples.
  • To investigate the potential of targeting specific genes for improved TNBC treatment.
  • To explore potential predictive biomarkers for TNBC treatment response.

Main Methods:

  • Real-time quantitative RT-PCR was used to analyze mRNA expression.
  • 26 key genes involved in cancer drug targeting were assessed in 63 TNBC samples.
  • Gene expression levels were compared across TNBC and other breast tumor subtypes.

Main Results:

  • Six genes (VEGFA, SRC, PARP1, PTK2, RAF1, FGFR3) were significantly upregulated in 13-46% of TNBCs.
  • No specific upregulation of these six genes was observed in TNBC compared to other breast tumor subtypes.
  • Overexpression of these genes, except FGFR3, showed no association with PIK3CA mutation status.

Conclusions:

  • VEGFA and PARP1 are confirmed as promising targets for TNBC clinical trials.
  • SRC, PTK2, RAF1, and FGFR3 represent novel potential therapeutic targets for TNBC.
  • These identified genes may serve as predictive biomarkers for TNBC treatment response, enabling easier clinical trial initiation with existing drugs.
Keywords:
breast cancertherapeutic targettriple negative

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...